Sensyne Health plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SSYNF research report →
Companywww.sensynehealth.com
Sensyne Health plc, a healthcare technology company, develops software products that connects healthcare professionals with patients in the United Kingdom and the United States. Its products include CVm-Health, a web-based application for Covid-19 self-monitoring; DBm-Health, a patient to clinician system that allows health care professionals manage patients with diabetes; GDm-Health, a prescribed digital therapeutic for remote management of diabetes in pregnancy; and BPm-Health that allows pregnant women to self-monitor blood pressure during pregnancy. The company's products also include MagnifEye that allows reading and analysis of diagnostic tests; SEND, an evidence-based digital charting system for vital-signs observations; EDGE, a prescribed digital therapeutic for monitoring chronic obstructive pulmonary disease at home; CleanSpace, a system for monitoring personal exposure to air pollution; Support-HF, a prescribed digital therapeutic for monitoring heart failure at home; Sense, a clinical AI algorithm engine; SYNE-COV, a COVID-19 patient outcome algorithm; and SYNE-OPS, a real-time operational patient management algorithm.
- CEO
- Alexander Charles Wallace Snow
- IPO
- 2020
- Employees
- 158
- HQ
- Oxford, GB
Price Chart
Valuation
- Market Cap
- $33.29K
- P/E
- -0.02
- P/S
- 0.00
- P/B
- 0.01
- EV/EBITDA
- 0.96
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 64.93%
- Op Margin
- -309.02%
- Net Margin
- -302.59%
- ROE
- -56.98%
- ROIC
- -49.62%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.70
- Avg Volume
- 0
Get TickerSpark's AI analysis on SSYNF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our SSYNF Coverage
We haven't published any research on SSYNF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SSYNF Report →